Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Practice Management

FDA: Policy Allows for Expanded Use of Certain Remote Patient Monitoring Devices

Brian Park, PharmD

April 1, 2020

The policy is intended to remain in effect only for the duration of the COVID-19 public health emergency declared by the Department of Health and Human Services (HHS).

Type 1 Diabetes

FDA Denies Approval of Empagliflozin for Type 1 Diabetes

Brian Park, PharmD

March 31, 2020

The FDA is unable to approve the sNDA for empagliflozin 2.5mg as an adjunct to insulin for type 1 diabetes in its current form.

Practice Management

FDA Issues Emergency Use Authorization for Point-of-Care COVID-19 Tests

Brian Park, PharmD

March 31, 2020

The FDA has issued emergency use authorization for two point-of-care diagnostics for the qualitative detection of SARS-CoV-2, the virus causing coronavirus disease 2019 (COVID-19).

Type 2 Diabetes

Empagliflozin Fast-Tracked for Chronic Kidney Disease Treatment

Brian Park, PharmD

March 25, 2020

The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.

General Endocrinology

Severe Illness Among Adults With COVID-19 Can Occur at Any Age, According to CDC Report

Brian Park, PharmD

March 24, 2020

The Centers for Disease Control and Prevention (CDC) released preliminary data related to outcomes among US patients with coronavirus disease 2019 (COVID-19).

Type 2 Diabetes

Update for SGLT2 Inhibitors: Temporary Discontinuation Prior to Surgery Recommended

Brian Park, PharmD

March 24, 2020

The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.

Obesity

Setmelanotide Receives Orphan Drug Status for Alström Syndrome

Brian Park, PharmD

March 20, 2020

The FDA has granted Orphan Drug designation to setmelanotide (Rhythm Pharmaceuticals) for the treatment of Alström Syndrome.

Diabetes

Insulin Pen With Bolus Calculator App Cleared by FDA for Fixed Dosing, Meal Estimation

Brian Park, PharmD

March 6, 2020

Companion Medical announced that it has received clearance from the Food and Drug Administration (FDA) for a new bolus calculator for fixed dosing and meal estimation to be used with the InPen system.

Cardiovascular and Metabolic Disorders

FDA Approves Bempedoic Acid, Ezetimibe Combination Therapy for LDL-C Lowering

Brian Park, PharmD

March 6, 2020

Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020.

Cardiovascular and Metabolic Disorders

FDA Approves First-in-Class Cholesterol-Lowering Therapy

Brian Park, PharmD

February 28, 2020

The FDA has approved Nexletol (bempedoic acid; Esperion) as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol.

Next post in Cardiovascular and Metabolic Disorders